Loading...
XHKG
2359
Market cap25bUSD
Apr 03, Last price  
64.15HKD
1D
-6.42%
1Q
21.50%
IPO
121.88%
Name

WuXi AppTec Co Ltd

Chart & Performance

D1W1MN
P/E
18.49
P/S
4.40
EPS
3.25
Div Yield, %
1.69%
Shrs. gr., 5y
4.29%
Rev. gr., 5y
33.22%
Revenues
40.34b
+2.51%
4,139,780,7794,883,348,9616,116,130,8887,765,259,8569,613,683,59312,872,206,43716,535,431,46522,902,385,12939,354,777,80540,340,806,877
Net income
9.61b
+9.00%
461,500,977348,967,672974,980,3141,227,093,4792,260,523,1061,854,550,9342,960,235,4955,097,155,2838,813,713,0339,606,749,135
CFO
13.39b
+26.10%
712,548,594738,595,7771,756,793,4171,793,610,2741,640,427,7642,916,032,3123,973,728,2224,589,288,73310,616,029,91613,386,911,778
Dividend
Jun 17, 20241.087 HKD/sh
Earnings
Jun 12, 2025

Profile

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
URL
https://www.wuxiapptec.com/
IPO date
May 08, 2018
Employees
41,296
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
40,340,807
2.51%
39,354,778
71.84%
Cost of revenue
26,262,987
27,949,979
Unusual Expense (Income)
NOPBT
14,077,820
11,404,798
NOPBT Margin
34.90%
28.98%
Operating Taxes
2,131,731
1,715,866
Tax Rate
15.14%
15.05%
NOPAT
11,946,089
9,688,932
Net income
9,606,749
9.00%
8,813,713
72.91%
Dividends
(2,649,084)
(1,529,442)
Dividend yield
1.23%
0.60%
Proceeds from repurchase of equity
(1,498,414)
BB yield
0.69%
Debt
Debt current
3,667,060
4,101,547
Long-term debt
2,884,121
2,748,714
Deferred revenue
910,922
Other long-term liabilities
1,610,039
148,013
Net debt
(18,851,299)
(11,292,742)
Cash flow
Cash from operating activities
13,386,912
10,616,030
CAPEX
(5,516,559)
Cash from investing activities
(7,955,623)
Cash from financing activities
(3,722,647)
FCF
7,861,098
(278,230)
Balance
Cash
14,560,841
7,987,741
Long term investments
10,841,639
10,155,261
Excess cash
23,385,440
16,175,263
Stockholders' equity
29,137,315
22,433,721
Invested Capital
39,194,673
36,794,737
ROIC
31.44%
29.64%
ROCE
22.50%
21.35%
EV
Common stock shares outstanding
2,965,046
3,125,430
Price
72.76
-10.17%
81.00
-31.69%
Market cap
215,736,749
-14.78%
253,159,842
-27.54%
EV
197,280,441
242,843,246
EBITDA
16,361,390
13,098,278
EV/EBITDA
12.06
18.54
Interest
120,283
159,837
Interest/NOPBT
0.85%
1.40%